bispecific antibody Clinical Research Trials

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (2)

Phase 1/2 (2)

Interventional (2)

Akeso (1)
BeiGene (1)

No (2)

No (2)

Adult (18+) (2)

I am/have/had

I am/have/haderbb2

I am/have/hadadenocarcinoma of the breast

I am/have/haddrug evaluation

I am/have/hadepidermal growth factor receptor

I am/have/hadlymphoma

I am/have/hadepidermal growth factor

I am/have/hadbreast cancer, treatment

I am/have/hadHER2

I am/have/hadbreast cancer

I am/have/hadcancer therapy

I am/have/hadrecurrent disease

I am/have/hadadenocarcinoma

I am/have/hadgastric adenocarcinoma

I am/have/hadadenocarcinoma of the gastroesophageal junction

I am/have/hadgastric cancer

I am/have/hadcancer treatment

I am/have/hadmeasurable disease

I am/have/hadher1

I am/have/hadmetastasis

I am/have/hadperipheral t-cell lymphoma

added new label for I am/have/had

I am looking for

I am looking forerbb2

I am looking fortislelizumab

I am looking foroxaliplatin

I am looking forepidermal growth factor

I am looking forgrowth factor

I am looking forhuman epidermal growth factor

I am looking fordocetaxel

I am looking forbispecific antibody

I am looking forcapecitabine

added new label for I am looking for

Advanced Filters

Found 2 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

Multi-country trial
Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Family Medicine
Recruiting

Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab

The purpose of the study is to assess the safety, tolerability and preliminary antitumor activity of ZW25 in combination with docetaxel in participants with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and ZW25 in combination with tislelizumab and chemotherapy in participants with HER2-positive gastric/gastroesophageal Junction (GEJ) adenocarcinoma

erbb2

adenocarcinoma of the breast

growth factor

docetaxel

recurrent disease

0 views
19 Feb, 2024

Phase 1
For Seniors
For adults
Recruiting in 10s
Interventional Study
all
Hematology
Recruiting

A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma

The purpose of this study is to evaluate the efficacy and safety of AK104an anti- PD-1 and CTLA-4 bispecific antibody, in subjects with relapsed or refractory peripheral T cell lymphoma. The subject will receive AK104 450mg Q2W until unacceptable toxicity, confirmed disease progression, withdrawal of consent, or for a maximum …

peripheral t-cell lymphoma

lymphoma

t-cell lymphoma

cancer

refractory peripheral t-cell lymphoma

0 views
19 Feb, 2024